SKAN Group AG
SIX:SKAN

Watchlist Manager
SKAN Group AG Logo
SKAN Group AG
SIX:SKAN
Watchlist
Price: 46.95 CHF -1.57%
Market Cap: CHf1.1B

EV/EBITDA

28.3
Current
16%
Cheaper
vs 3-y average of 33.5

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
28.3
=
Enterprise Value
CHf986.6m
/
EBITDA
CHf38.6m

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
28.3
=
Enterprise Value
CHf986.6m
/
EBITDA
CHf38.6m

Valuation Scenarios

SKAN Group AG is trading below its 3-year average

If EV/EBITDA returns to its 3-Year Average (33.5), the stock would be worth CHf55.66 (19% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-55%
Maximum Upside
+24%
Average Downside
7%
Scenario EV/EBITDA Value Implied Price Upside/Downside
Current Multiple 28.3 CHf46.95
0%
3-Year Average 33.5 CHf55.66
+19%
5-Year Average 34.9 CHf58
+24%
Industry Average 24.2 CHf40.17
-14%
Country Average 12.7 CHf21.09
-55%

Forward EV/EBITDA
Today’s price vs future ebitda

Today's Enterprise Value EBITDA Forward EV/EBITDA
CHf986.6m
/
Jan 2026
CHf38.6m
=
28.3
Current
CHf986.6m
/
Dec 2026
CHf55.3m
=
17.8
Forward
CHf986.6m
/
Dec 2027
CHf69.6m
=
14.2
Forward
CHf986.6m
/
Dec 2028
CHf88.3m
=
11.2
Forward

Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.

Peer Comparison

All Multiples
EV/EBITDA
P/E
All Countries
Close
Market Cap EV/EBITDA P/E
CH
SKAN Group AG
SIX:SKAN
1.1B CHF 28.3 65.9
US
PerkinElmer Inc
LSE:0KHE
1T USD 1 226.4 4 280.5
US
Thermo Fisher Scientific Inc
NYSE:TMO
175.6B USD 18.3 26.2
US
Danaher Corp
NYSE:DHR
126.4B USD 17.7 34.3
KR
Samsung Biologics Co Ltd
KRX:207940
82.3T KRW 30.1 46.1
CN
WuXi AppTec Co Ltd
SSE:603259
298.9B CNY 16.3 15.6
CH
Lonza Group AG
SIX:LONN
34.3B CHF 16.3 -119.7
US
Agilent Technologies Inc
NYSE:A
32.3B USD 18.4 25.1
US
Waters Corp
NYSE:WAT
30.5B USD 30.7 47.5
US
IQVIA Holdings Inc
NYSE:IQV
27.3B USD 11.4 20.1
US
Mettler-Toledo International Inc
NYSE:MTD
25.7B USD 22 29.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CH
SKAN Group AG
SIX:SKAN
Average EV/EBITDA: 130.5
28.3
32%
0.9
US
P
PerkinElmer Inc
LSE:0KHE
1 226.4
9%
136.3
US
Thermo Fisher Scientific Inc
NYSE:TMO
18.3
9%
2
US
Danaher Corp
NYSE:DHR
17.7
7%
2.5
KR
Samsung Biologics Co Ltd
KRX:207940
30.1
12%
2.5
CN
WuXi AppTec Co Ltd
SSE:603259
16.3
23%
0.7
CH
Lonza Group AG
SIX:LONN
16.3
12%
1.4
US
Agilent Technologies Inc
NYSE:A
18.4
12%
1.5
US
Waters Corp
NYSE:WAT
30.7
36%
0.9
US
IQVIA Holdings Inc
NYSE:IQV
11.4
10%
1.1
US
Mettler-Toledo International Inc
NYSE:MTD
22
7%
3.1

Market Distribution

Higher than 82% of companies in Switzerland
Percentile
82st
Based on 1 007 companies
82st percentile
28.3
Low
0 — 9.2
Typical Range
9.2 — 20.5
High
20.5 —
Distribution Statistics
Switzerland
Min 0
30th Percentile 9.2
Median 12.7
70th Percentile 20.5
Max 1 129.6

SKAN Group AG
Glance View

SKAN Group AG, headquartered in Switzerland, has carved out its niche as a leading innovator in the realm of contamination control for aseptic environments. The company's history traces back to its founding in 1968, following the rapid advancements in the pharmaceutical and biotechnology sectors. SKAN has since developed a sterling reputation for its pioneering work in isolator technology, offering solutions that ensure the highest standards of sterility and safety critical to these industries. The company designs and manufactures isolators, which are essentially sealed environments that provide contamination-free zones for the processing of materials or production of pharmaceuticals, ensuring that even the most sensitive products are handled with stringent safety measures. This focus on high-tech, specialized equipment forms the backbone of SKAN's revenue model. By providing bespoke solutions tailored to the unique requirements of its clients, SKAN taps into the lucrative markets of pharmaceutical production and research, biotechnology companies, and laboratories that demand high-performance contamination barriers. Beyond just the sale of equipment, SKAN also offers a comprehensive suite of services, including installation, validation, maintenance, and training, ensuring a steady flow of income as these businesses need continual updates and technical support for their critical infrastructure. The demand for stricter health regulations and more advanced pharmaceuticals continues to rise, positioning SKAN Group AG as a pivotal player in this essential industry, capitalizing on its expertise to ensure both safety and compliance for its customers worldwide.

SKAN Intrinsic Value
68.31 CHF
Undervaluation 31%
Intrinsic Value
Price CHf46.95
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett